Cite
HARVARD Citation
Aisen, P. et al. (n.d.). AHEAD 3‐45 study design: A global study to evaluate the efficacy and safety of treatment with BAN2401 for 216 weeks in preclinical Alzheimer's disease with intermediate amyloid (A3 trial) and elevated amyloid (A45 trial). Alzheimer's & dementia. p. n/a. [Online].